PMID- 19900123
OWN - NLM
STAT- MEDLINE
DCOM- 20100407
LR  - 20181201
IS  - 1651-226X (Electronic)
IS  - 0284-186X (Linking)
VI  - 49
IP  - 1
DP  - 2010
TI  - Targeted therapies in the treatment of GIST: Adverse events and maximising the 
      benefits of sunitinib through proactive therapy management.
PG  - 13-23
LID - 10.3109/02841860903287205 [doi]
AB  - BACKGROUND AND OBJECTIVES: The introduction of targeted therapies has led to 
      improved clinical outcomes in patients with unresectable gastrointestinal stromal 
      tumours (GIST). The receptor tyrosine kinase (RTK) inhibitor imatinib mesylate 
      has been approved as the first-line choice of therapy for this group of patients, 
      while the RTK inhibitor, sunitinib malate, has been approved for the treatment of 
      GIST after disease progression or intolerance to imatinib. Here we discuss and 
      compare the tolerability profiles of imatinib and sunitinib based on published 
      clinical trial data. We also review available data on the potential mechanisms by 
      which these agents may cause adverse events (AEs) and we propose some general 
      strategies to help clinicians to optimise treatment benefit with these agents. 
      FINDINGS: While the toxicity profiles of imatinib and sunitinib are well known, 
      the mechanisms of toxicity of these agents have yet to be elucidated fully. 
      Clinical observations along with retrospective and prospective analyses suggest 
      that some RTK inhibitor-related AEs have a higher incidence than previously 
      reported from clinical trials. In addition, with greater use, new and unexpected 
      AEs are emerging. Clinicians need to be familiar with the toxicity profiles of 
      RTK inhibitors as well as individual patient risk factors in order to optimise 
      treatment benefit. CONCLUSIONS: Imatinib and sunitinib are generally well 
      tolerated with known and manageable AE profiles. Proactive therapy management 
      strategies can enable treatment optimisation and allow patients to continue 
      treatment with minimal interruption.
FAU - Wolter, Pascal
AU  - Wolter P
AD  - Department of General Medical Oncology, University Hospitals Leuven, Leuven 
      Cancer Institute, B-3000 Leuven, Belgium. Pascal.Wolter@uz.kuleuven.be
FAU - Schoffski, Patrick
AU  - Schoffski P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Sweden
TA  - Acta Oncol
JT  - Acta oncologica (Stockholm, Sweden)
JID - 8709065
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Indoles)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Benzamides
MH  - Clinical Trials as Topic
MH  - Gastrointestinal Stromal Tumors/*drug therapy
MH  - Humans
MH  - Imatinib Mesylate
MH  - Indoles/*adverse effects
MH  - Piperazines/*adverse effects
MH  - Pyrimidines/*adverse effects
MH  - Pyrroles/*adverse effects
MH  - Sunitinib
RF  - 76
EDAT- 2009/11/11 06:00
MHDA- 2010/04/08 06:00
CRDT- 2009/11/11 06:00
PHST- 2009/11/11 06:00 [entrez]
PHST- 2009/11/11 06:00 [pubmed]
PHST- 2010/04/08 06:00 [medline]
AID - 10.3109/02841860903287205 [pii]
AID - 10.3109/02841860903287205 [doi]
PST - ppublish
SO  - Acta Oncol. 2010;49(1):13-23. doi: 10.3109/02841860903287205.